Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
0.43
Industry P/E
--
Debt to Equity
0
ROE
-0.27 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-251.62 Mln
EBITDA
$-284.82 Mln
Net Profit
$-364.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Windtree Therapeutics (WINT)
| -93.53 | -27.56 | -84.06 | -99.57 | -91.63 | -86.45 | -76.77 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Windtree Therapeutics (WINT)
| -51.20 | -91.53 | -89.43 | -68.62 | -59.76 | -15.00 | 18.93 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.68 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 306.35 | 8,705.27 | 22.77 | 66.44 | |
| 27.94 | 2,881.32 | -- | -14.59 |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the... treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Address: 2600 Kelly Road, Warrington, PA, United States, 18976-3622 Read more
Chairman, President, CEO & Interim Principal Officer
Mr. Craig E. Fraser
Chairman, President, CEO & Interim Principal Officer
Mr. Craig E. Fraser
Headquarters
Warrington, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Windtree Therapeutics Inc (WINT) stood at $ 30 Mln as on 31-Mar-25
The share price of Windtree Therapeutics Inc (WINT) is $1.13 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Windtree Therapeutics Inc (WINT) has given a return of -91.63% in the last 3 years.
Windtree Therapeutics Inc (WINT) has a market capitalisation of $ 4 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Windtree Therapeutics Inc (WINT) is 0.43 times as on 28-Apr-2025, a 81% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Windtree Therapeutics Inc (WINT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Windtree Therapeutics Inc (WINT) and enter the required number of quantities and click on buy to purchase the shares of Windtree Therapeutics Inc (WINT).
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Address: 2600 Kelly Road, Warrington, PA, United States, 18976-3622
The CEO & director of Mr. Craig E. Fraser. is Windtree Therapeutics Inc (WINT), and CFO & Sr. VP is Mr. Craig E. Fraser.
There is no promoter pledging in Windtree Therapeutics Inc (WINT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
867
|
|
|
290
|
|
|
80
|
|
|
8
|
| Windtree Therapeutics Inc. (WINT) | Ratios |
|---|---|
|
Return on equity(%)
|
-179.65
|
|
Operating margin(%)
|
-26071.11
|
|
Net Margin(%)
|
-28753.33
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Windtree Therapeutics Inc (WINT) was $0 Mln.
$-0.01
(
